R1 RCM Inc. (RCM)
NASDAQ: RCM · IEX Real-Time Price · USD
12.45
+0.09 (0.73%)
At close: May 2, 2024, 4:00 PM
12.50
+0.05 (0.40%)
After-hours: May 2, 2024, 7:59 PM EDT

R1 RCM Revenue

In the year 2023, R1 RCM had annual revenue of $2.25B with 24.79% growth. Revenue in the quarter ending December 31, 2023 was $575.10M with 7.84% year-over-year growth.

Revenue (ttm)
$2.25B
Revenue Growth
+24.79%
P/S Ratio
2.32
Revenue / Employee
$75,140
Employees
30,000
Market Cap
5.23B USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20232.25B447.80M24.79%
Dec 31, 20221.81B331.80M22.50%
Dec 31, 20211.47B204.50M16.10%
Dec 31, 20201.27B84.00M7.08%
Dec 31, 20191.19B317.60M36.57%
Dec 31, 2018868.50M418.70M93.09%
Dec 31, 2017449.80M-142.80M-24.10%
Dec 31, 2016592.60M475.40M405.63%
Dec 31, 2015117.20M-92.94M-44.23%
Dec 31, 2014210.14M-294.63M-58.37%
Dec 31, 2013504.77M432.51M598.60%
Dec 31, 201272.25M-29.71M-29.14%
Dec 31, 2011101.97M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Grifols 7.32B
Organon & Co. 6.26B
Option Care Health 4.43B
Bausch + Lomb 4.31B
DENTSPLY SIRONA 3.94B
Lantheus Holdings 1.37B
Halozyme Therapeutics 829.25M
Apellis Pharmaceuticals 396.59M
Revenue Rankings